

Pediapharm  10 yrs
Canada's Leading Pediatric Pharmaceutical Company

Building on our **HISTORY**

2008 • 2018

CELEBRATING 10 YEARS



Our Financial Growth



Note from the President



A handwritten signature in black ink, appearing to read 'S. Chrétien'.

Sylvain Chrétien
President

The idea of founding Pediapharm came about in 2003 while I was studying for my MBA. Following an in-depth analysis of the pharmaceutical industry and its future trends, I have concluded that major pharmaceutical companies were abandoning certain growth markets, particularly pediatric medicines.

A report published in 2011 reveals that only 30 % of drugs sold in global markets have pediatric indications. A 2014 report also raises the fact that pharmaceutical products indicated only for adult were too often given to children, and that these products may not be suitable for their physiological needs.

Meanwhile, Canada needs to quickly align itself with Europe and the United States on children's access to innovative medicines. Hence the urgent need to fill the gaps in the pharmaceutical market and seize the business opportunity that represents Pediapharm.

There is no doubt that the success achieved would never have been possible without the leadership of a seasoned management team and the constant effort of all our employees and representatives. I would like to thank our Chairman of the Board Mr. Pierre Lapalme, and all the directors for their continued support, as well as the investors who believe in our mission since the beginning.

We are very proud of the success obtained in the last 10 years and will use it to build on our future. The new opportunities and our upcoming and promising financial results will help contribute to our sustainable economic growth.

In conclusion, know that the best is yet to come!

Our Company History

Suprax

Commercial agreement co-promotion with Sanofi for Suprax
(acute otitis media)

Board of director establishment with Mr. Pierre Lapalme as Chairman

Sales Force Expansion

Vapolyptus

Vapolyptus launch
(soothing vapour)

TSX.V listing under the symbol PDP

2008



2009



2010



2011



2012



2013



EpiCeram

EpiCeram launch
(eczema)

NYDA

NYDA launch
(head lice)

Allerject

Commercial agreement co-promotion with Sanofi for Allerject
(severe allergic reaction)

Naproxen

Naproxen
Suspension Product
right acquisition for
Canada and USA

*(juvenile rheumatoid
arthritis and pain
symptoms)*

Relaxa

Licensing
agreement
for Relaxa

*(occasional
constipation)*

Rupall

Rupall launch

*(seasonal and
perennial allergy
rhinitis, urticaria)*

Cuvposa

Cuvposa launch

(severe drooling)

2014

2015

2016

2017

2018



Naproxen

Selling US
right of Naproxen
Suspension

Otixal

Otixal launch

*(ear infection-
externa)*

Pediapharm

10th
year
anniversary

Note from the President of the Board of Directors

Our Board Members

Normand Chartrand
Benoit Gravel
Michael Mueller

10 years ago Sylvain Chrétien had this project of founding PEDIAPHARM.

Armed with a solid business plan, a ton of determination and surrounded by experienced colleagues, the company he founded has successfully overcome all obstacles it has faced to this day. We must also recognize support provided by all of our financial partners throughout the years.

Nowadays, PEDIAPHARM is a renowned and respected company endorsed by the Canadian pediatric healthcare industry.

I have the privilege and honour of being associated with the company.

Best wishes of continued success!



Pierre Lapalme
Chairman of the Board of Directors



Our Team

Sylvain • Benoît • Roland • Richard • Francine • Sébastien • Jean-Claude • Myriam • Agostino
Marie-Josée • Danny • Lee • Quinn • Patrick • Gerardo • Therese • Kimberlee • Sylvie • Christina
Susie • Jonathan • Marie-Christine • Susan • Andrea



Our Partners▶

